#Spain #gene therapy #Viralgen #Angela Ochoa #Saint-Sébastien

Viralgen's Leadership Transition: A New Era in Gene Therapy

Viralgen, a prominent contract development and manufacturing organization (CDMO) focused on adeno-associated virus (AAV) gene therapies, is undergoing a significant leadership change. On October 19, 2026, the current CEO, Jimmy Vanhove, announced his transition to a new role that involves overseeing the pharmaceutical supply network at Bayer in the United States. This change marks a pivotal moment for the organization as it prepares for new leadership under Angela Ochoa Chico, who will take over the CEO position beginning January 1, 2027.

Vanhove's tenure at Viralgen has been marked by remarkable growth. Under his leadership, the company transformed from an emerging CDMO into a market leader specializing in AAV manufacturing. During his four years at the helm, Viralgen expanded its facilities and developed an integrated manufacturing process, earning the trust of over 70 clients worldwide. His focus on quality, operational reliability, and sustainability has solidified Viralgen's reputation in the gene therapy industry, with a commitment to meet the needs of patients suffering from rare diseases.

Reflecting on his time at the company, Vanhove expressed pride in Viralgen's dedication to advancing innovative gene therapies despite its rapid growth. He stated, "I am proud that we have remained committed to patients with both common and rare diseases and to the patient advocacy groups that represent them. I am confident that Angela will build on this legacy and lead Viralgen into an exciting new chapter."

Angela Ochoa Chico: A Leader for the Future

Angela Ochoa Chico joins Viralgen with almost two decades of international experience in pharmaceutical operations, quality management, and manufacturing. Prior to her new role, she held a significant position at Bayer, focusing on product supply chain strategy and excellence, where she contributed to developing global manufacturing strategies and enhancing organizational capabilities.

Ochoa Chico’s leadership is anticipated to steer Viralgen towards greater production capabilities while maintaining its high standards of scientific excellence and innovation. Her appointment signals a strategic move towards expanding the company's influence in the gene therapy landscape. She stated, "I am thrilled to join Viralgen at such a critical stage of its evolution. The company has established an outstanding reputation for scientific excellence and quality. I look forward to building on these solid foundations, enhancing our production capabilities, and further establishing Viralgen as a trusted partner in gene therapy manufacturing."

A Commitment to Quality and Patient Care

Viralgen’s mission to make revolutionary gene therapies accessible to patients remains at the core of its operations. With over 450 professionals working in its cutting-edge facility in Saint-Sébastien, Spain, the company operates one of the world's largest dedicated AAV manufacturing sites. This facility is equipped with advanced capabilities covering process development, clinical and commercial production, quality control, and fill-finish services. Viralgen has produced over 2,000 AAV batches, providing reliable and efficient solutions to accelerate life-changing therapies for patients in need.

The leadership transition is a natural progression that reflects Viralgen’s continued dedication to advancing gene therapy. As it embarks on this new chapter with Angela Ochoa Chico at the helm, the company is poised to expand its contributions to the healthcare sector, with a clear focus on innovation, quality, and patient impact.

Conclusion

In conclusion, the leadership change at Viralgen conveys an optimistic future imbued with promise and potential for growth. As the organization sets to harness Angela Ochoa Chico's extensive experience and leadership, the passion for patient welfare remains unchanged. This transition not only marks a new beginning for management but also reaffirms Viralgen's goal of bridging the gap between life-changing therapies and patients who are in dire need of solutions. As they strive to further enhance their offerings, all eyes will be on how this evolving leadership will shape the future of gene therapy manufacturing.